Zenith Epigenetics Corp
44 Montgomery Street
About Zenith Epigenetics Corp
Zenith Epigenetics is a clinical stage biotechnology company with a broad and deep drug discovery platform in epigenetics, developing orally active, small molecules that are selective for inhibition of BET bromodomains. This platform integrates structural biology, modeling, medicinal chemistry with biochemical and cell-based assays to discover potent compounds which are then further evaluated for desirable pharmaceutical properties, including oral bioavailability, and in animal models of disease. Through ongoing discovery activities we are continuing to secure intellectual property around novel compounds and their analogs.
CEO: Donald J. McCaffrey
CBO: Sanjay Lakhotia
CFO: A. Brad Cann
Please click here for Zenith Epigenetics job opportunities.
Please click here for clinical trial information.
7 articles with Zenith Epigenetics Corp
Zenith Epigenetics Announces Clinical Collaboration with AstellasTo Evaluate the Combination of ZEN-3694 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer
Zenith Epigenetics Ltd. (“Zenith” or the “Company”), a clinical stage biotechnology company focused on the development of novel epigenetic combination therapies for the treatment of cancers, announces it has entered into an agreement with Astellas Pharma Inc. (“Astellas”) to evaluate ZEN-3694, Zenith’s leading BET inhibitor, in combination with Astellas and Pfizer’s androgen receptor inhibitor, XTANDI (enzalutamide)
Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA
Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today the dosing of first patient with a triple combination of ZEN-3694 + Merck’s immune check point inhibitor, KEYTRUDA, + Pfizer’s androgen receptor signaling inhibitor (ARSI), XTANDI, in a University of California, San Francisco (UCSF) investigator led metastatic castration resistant prostate cancer (mCRPC) Phase 2 clinical trial. ZEN-3694
Zenith Epigenetics Announces Collaboration with NCI in Developing ZEN-3694 for Multiple Oncology IndicationsFirst Clinical Study to Combine ZEN-3694 with BMS’s Immune Checkpoint Inhibitors nivolumab and ipilimumab for Treatment of Ovarian Cancer
Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today the execution of a cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI) to develop ZEN-3694 for multiple oncology indications. For the first clinical study under the CRADA, NCI is co-collaborating with Zenith and Bristol Myers Squibb (BMS) to investigate the combination of Zenith’s epigenetic therapy – BET inhibitor ZEN-3694 – with i
Zenith Epigenetics Advances ZEN-3694 in Multiple Cancer ProgramsMerck to Collaborate with UCSF and Zenith in a New Phase 2 mCRPC Clinical Trial
Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today significant clinical advances of ZEN-3694, the Company’s lead therapeutic compound being developed for epigenetic combination therapies in multiple oncology indications. “Merck, Pfizer, UCSF and Newsoara now form an impressive list of collaborators involved in our development of ZEN-3694 in epigenetic combination therapy programs. We have made significant progress with ZEN-
Zenith Epigenetics Ltd. announced the significant clinical advances of ZEN-3694, the Company’s lead compound being developed for epigenetic combination therapies in oncology.
Zenith Epigenetics Ltd. (“Zenith” or the “Company”), announced today that it has entered into a clinical trial collaboration with Pfizer Inc. (“Pfizer”; NYSE: PFE) to evaluate the safety and efficacy of a novel anti-cancer combination of Zenith’s investigational bromodomain and extra-terminal domain inhibitor (“BETi”), ZEN-3694,